- Home
- FOLD vs HCM Comparison
FOLD vs HCM Comparison
Compare FOLD & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOLD | HCM |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | FOLD | HCM |
|---|---|---|
| Price | $14.19 | $13.50 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $29.79 | $13.75 |
| AVG Volume (30 Days) | ★ 14.8M | 21.1K |
| Earning Date | 11-04-2025 | 08-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $598,704,000.00 | ★ $602,197,000.00 |
| Revenue This Year | $21.49 | N/A |
| Revenue Next Year | $18.25 | $15.54 |
| P/E Ratio | ★ N/A | $4.90 |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $5.51 | $11.51 |
| 52 Week High | $14.36 | $19.50 |
Technical Indicators
Market Signals| Indicator | FOLD | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 91.10 | 35.07 |
| Support Level | $10.64 | $13.06 |
| Resistance Level | $11.14 | $13.79 |
| Average True Range (ATR) | 0.36 | 0.23 |
| MACD | 0.28 | -0.02 |
| Stochastic Oscillator | 96.46 | 32.91 |
Price Performance
Historical ComparisonAbout FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.